首页> 外国专利> ANTI-HLA-DQ2.5/8 ANTIBODY AND ITS USE FOR THE TREATMENT OF CELIAC DISEASE

ANTI-HLA-DQ2.5/8 ANTIBODY AND ITS USE FOR THE TREATMENT OF CELIAC DISEASE

机译:ANTI-HLA-DQ2.5 / 8抗体及其在治疗宫颈癌中的应用

摘要

The invention provides anti-HLA-DQ2.5/8 antibodies and methods of using the same. The antibodies of the present invention have binding activity to human HLA-DQ2.5/8 and monkey MHC-DQ, but substantially no binding activity to HLA-DR, HLA-DP, or a complex of the invariant chain (CD74) and HLA-DQ2.5/8. The antibodies bind to HLA-DQ2.5/8 in the presence of a gluten peptide such as gliadin, i.e., bind to HLA-DQ2.5/8 forming a complex with the gluten peptide. The antibodies have neutralizing activity against the binding between HLA-DQ2.5/8 and TCR, and thus block the interaction between HLA-DQ2.5/8 and an HLA-DQ2.5/8-restricted CD4+ T cell. The antibodies do not undergo rapid internalization mediated by the invariant chain. These characteristics are particularly useful for treating celiac disease. Thus, the present invention also provides a method of treating celiac disease using the antibodies of the present invention.
机译:本发明提供了抗HLA-DQ2.5 / 8抗体及其使用方法。本发明的抗体对人HLA-DQ2.5 / 8和猴MHC-DQ具有结合活性,但对HLA-DR,HLA-DP或不变链(CD74)和HLA的复合物基本上不具有结合活性。 -DQ2.5 / 8。在谷蛋白肽例如麦醇溶蛋白的存在下,抗体与HLA-DQ2.5 / 8结合,即,与HLA-DQ2.5 / 8结合,与谷蛋白肽形成复合物。抗体对HLA-DQ2.5 / 8和TCR之间的结合具有中和活性,因此可以阻断HLA-DQ2.5 / 8和HLA-DQ2.5 / 8限制性CD4 + T细胞之间的相互作用。抗体不经历由恒定链介导的快速内在化。这些特征对于治疗乳糜泻特别有用。因此,本发明还提供了使用本发明的抗体治疗乳糜泻的方法。

著录项

  • 公开/公告号US2020040085A1

    专利类型

  • 公开/公告日2020-02-06

    原文格式PDF

  • 申请/专利权人 CHUGAI SEIYAKU KABUSHIKI KAISHA;

    申请/专利号US201816488336

  • 发明设计人 YUU OKURA;NORIYUKI TAKAHASHI;

    申请日2018-02-26

  • 分类号C07K16/28;A61P1;A61P37/06;G01N33/577;

  • 国家 US

  • 入库时间 2022-08-21 11:19:14

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号